pA-Tn5 transposase is a fusion protein of hyperactive Tn5 transposase and protein A developed for the CUT&Tag assay. For convenience, the fusion protein is pre-loaded with sequencing adapters. Diagenode pA-Tn5 transposase is compatible with CUT&Tag and other antibody-tethered Tn5 based methods, like ACT-seq and CoBATCH.
pA-Tn5 Transposase
High enrichment and specificity of the signal around the TSS
As it is crucial to target only the protein of interest, a highly specific antibody is critical for the success of the CUT&Tag assay. All Diagenode ChIP-seq grade antibodies are validated for specificity using strict validation criteria to assure high performance in CUT&Tag.
Check out all products recommended for CUT&Tag assay:
Figure 1. Representative screenshots for H3K4me3 (A), H3K9me3 (B) and H3K27me3 (C) data obtained using Diagenode pA-Tn5 fusion protein (C01070001) and CUT&Tag protocol (Kaya-Okur, H.S., Nat Commun 10, 1930 (2019)) at selected loci. CUT&Tag was performed using 50,000 of K562 cells and Diagenode H3K4me3 polyclonal ChIP-seq antibody (Cat. No. C15410003), H3K27me3 polyclonal ChIP-seq grade antibody (Cat. No. C15410195) and H3K9me3 polyclonal ChIP-seq grade antibody (Cat. No. C15410193).
Figure 2. CUT&Tag profiles show typical enrichments specific for a given histone mark. Representative screenshots for H3K27me3 (red) and H3K4me3 (green) are shown at selected loci. H3K27me3, which marks inactive regions (red), does not show enrichment over open chromatin regions, marked by H3K4me3 (green). CUT&Tag was performed using 50,000 of K562 cells and Diagenode H3K4me3 polyclonal ChIP-seq antibody (Cat. No. C15410003), and H3K27me3 polyclonal ChIP-seq grade (Cat. No.C15410195).
Diagenode strongly recommends using this: pA-Tn5 Transposase - loaded (Diagenode Cat# C01070001). Click here to copy to clipboard.
Using our products in your publication? Let us know!
ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma Babikir, H., Wang, L., Shamardani, K. et al.
Background
Recent single-cell transcriptomic studies report that IDH-mutant gliomas share a common hierarchy of cellular phenotypes, independent of genetic subtype. However, the genetic differences between IDH-mutant glioma subtypes are prognostic, predictive of response to chemotherapy, and correlate with distin...
To ensure you see the information most relevant to you, please select your country.
Please note that your browser will need to be configured to accept cookies.
Diagenode will process your personal data in strict accordance with its privacy policy. This will include sending you updates about us, our products, and resources we think would be of interest to you.
